Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens

被引:190
作者
Linnebacher, M
Gebert, J
Rudy, W
Woerner, S
Yuan, YP
Bork, P
Doeberitz, MV
机构
[1] Heidelberg Univ, Chirurg Klin, Sekt Mol Diagnost & Therapie, D-69120 Heidelberg, Germany
[2] Heidelberg Univ, Inst Immunol, D-69120 Heidelberg, Germany
[3] MTM Labs AG, Heidelberg, Germany
[4] EMBL, Heidelberg, Germany
[5] Max Delbruck Ctr Mol Med, Berlin, Germany
关键词
DNA mismatch repair; microsatellite instability; frameshift peptides; tumor antigens; T-cell epitopes;
D O I
10.1002/ijc.1298
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Microsatellite instability (MSI) caused by defective DNA mismatch repair (MMR) is a hallmark of hereditary nonpolyposis colorectal cancers (HNPCC) but also occurs in about 15% of sporadic tumors. If instability affects microsatellites in coding regions, translational frameshifts lead to truncated proteins often marked by unique frameshift peptide sequences at their C-terminus. Since MSI tumors show enhanced lymphocytic infiltration and our previous analysis identified numerous coding mono- and dinucleotide repeat-bearing candidate genes as targets of genetic instability, we examined the role of frameshift peptides in triggering cellular immune responses. Using peptide pulsed autologous CD40-activated B cells, we have generated cytotoxic T lymphocytes (CTL) that specifically recognize HLA-A2.I-restricted peptides derived from frameshift sequences. Among 16 frameshift peptides predicted from mutations in 8 different genes, 3 peptides conferred specific lysis of target cells exogenously loaded with cognate peptide, One peptide derived from a (-I) frameshift mutation in the TGF beta IIR gene gave rise to a CTL bulk culture capable of lysing the MSI colorectal cancer cell line HCTII6 carrying this frameshift mutation. Given the huge number of human coding microsatellites and assuming only a fraction being mutated and encoding immunologically relevant peptides in MSI tumors, frameshift protein sequences represent a novel subclass of tumor-specific antigens, It is tempting to speculate that a frameshift peptide-directed vaccination approach not only could offer new treatment modalities for existing MSI tumors but also might benefit asymptomatic at-risk individuals in HNPCC families by a prophylactic vaccination strategy. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:6 / 11
页数:6
相关论文
共 45 条
[1]  
Aarnoudse CA, 1999, INT J CANCER, V82, P442, DOI 10.1002/(SICI)1097-0215(19990730)82:3<442::AID-IJC19>3.3.CO
[2]  
2-Q
[3]   Selection for beta(2)-microglobulin mutation in mismatch repair-defective colorectal carcinomas [J].
Bicknell, DC ;
Kaklamanis, L ;
Hampson, R ;
Bodmer, WF ;
Karran, P .
CURRENT BIOLOGY, 1996, 6 (12) :1695-1697
[4]   Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptide [J].
Brossart, P ;
Bevan, MJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (06) :2449-2458
[5]   Mammalian DNA mismatch repair [J].
Buermeyer, AB ;
Deschênes, SM ;
Baker, SM ;
Liskay, RM .
ANNUAL REVIEW OF GENETICS, 1999, 33 :533-564
[6]   High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability [J].
Dolcetti, R ;
Viel, A ;
Doglioni, C ;
Russo, A ;
Guidoboni, M ;
Capozzi, E ;
Vecchiato, N ;
Macrì, E ;
Fornasarig, M ;
Boiocchi, M .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (06) :1805-1813
[7]  
Duval A, 1999, CANCER RES, V59, P4213
[8]   IN-VITRO INDUCTION OF HUMAN CYTOTOXIC T-LYMPHOCYTE RESPONSES AGAINST PEPTIDES OF MUTANT AND WILD-TYPE P53 [J].
HOUBIERS, JGA ;
NIJMAN, HW ;
VANDERBURG, SH ;
DRIJFHOUT, JW ;
KENEMANS, P ;
VANDEVELDE, CJH ;
BRAND, A ;
MOMBURG, F ;
KAST, WM ;
MELIEF, CJM .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (09) :2072-2077
[9]   UBIQUITOUS SOMATIC MUTATIONS IN SIMPLE REPEATED SEQUENCES REVEAL A NEW MECHANISM FOR COLONIC CARCINOGENESIS [J].
IONOV, Y ;
PEINADO, MA ;
MALKHOSYAN, S ;
SHIBATA, D ;
PERUCHO, M .
NATURE, 1993, 363 (6429) :558-561
[10]  
Jager E, 1997, INT J CANCER, V71, P142, DOI 10.1002/(SICI)1097-0215(19970410)71:2<142::AID-IJC3>3.0.CO